Business Description
Insmed Inc
NAICS : 325412
SIC : 2834
ISIN : US4576693075
Share Class Description:
STU:IM8N: Ordinary SharesDescription
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.47 | |||||
| Equity-to-Asset | 0.24 | |||||
| Debt-to-Equity | 2.07 | |||||
| Debt-to-EBITDA | -1.3 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.09 | |||||
| Beneish M-Score | -2.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.9 | |||||
| 3-Year EBITDA Growth Rate | -22.4 | |||||
| 3-Year EPS without NRI Growth Rate | -21.5 | |||||
| 3-Year FCF Growth Rate | -19.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 24.79 | |||||
| Future 3-5Y Total Revenue Growth Rate | 49.82 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.8 | |||||
| 9-Day RSI | 64.75 | |||||
| 14-Day RSI | 60.69 | |||||
| 6-1 Month Momentum % | 224.26 | |||||
| 12-1 Month Momentum % | 200.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.37 | |||||
| Quick Ratio | 5.99 | |||||
| Cash Ratio | 5.66 | |||||
| Days Inventory | 404.75 | |||||
| Days Sales Outstanding | 41.84 | |||||
| Days Payable | 272.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.9 | |||||
| Shareholder Yield % | 0.21 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.25 | |||||
| Operating Margin % | -205.25 | |||||
| Net Margin % | -252.01 | |||||
| FCF Margin % | -185.3 | |||||
| ROA % | -56.29 | |||||
| ROIC % | -124.88 | |||||
| ROC (Joel Greenblatt) % | -730.46 | |||||
| ROCE % | -64.51 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 34.26 | |||||
| PB Ratio | 28 | |||||
| Price-to-Tangible-Book | 46.73 | |||||
| EV-to-EBIT | -16.72 | |||||
| EV-to-Forward-EBIT | -20.46 | |||||
| EV-to-EBITDA | -16.96 | |||||
| EV-to-Forward-EBITDA | -18.39 | |||||
| EV-to-Revenue | 38.04 | |||||
| EV-to-Forward-Revenue | 22.73 | |||||
| EV-to-FCF | -20.55 | |||||
| Price-to-Net-Current-Asset-Value | 166.28 | |||||
| Earnings Yield (Greenblatt) % | -5.98 | |||||
| FCF Yield % | -4.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Insmed Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 314.308 | ||
| EPS (TTM) (€) | -5.095 | ||
| Beta | 0.58 | ||
| Volatility % | 121.2 | ||
| 14-Day RSI | 60.69 | ||
| 14-Day ATR (€) | 2.0317 | ||
| 20-Day SMA (€) | 66.55 | ||
| 12-1 Month Momentum % | 200.46 | ||
| 52-Week Range (€) | 20 - 72 | ||
| Shares Outstanding (Mil) | 178.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Insmed Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Insmed Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Insmed Inc Frequently Asked Questions
What is Insmed Inc(STU:IM8N)'s stock price today?
The current price of STU:IM8N is €71.50. The 52 week high of STU:IM8N is €72.00 and 52 week low is €20.00.
When is next earnings date of Insmed Inc(STU:IM8N)?
The next earnings date of Insmed Inc(STU:IM8N) is 2025-02-21 Est..
Does Insmed Inc(STU:IM8N) pay dividends? If so, how much?
Insmed Inc(STU:IM8N) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers